ClinicalTrials.gg
Not yet recruitingNCT05848830DM1HBETUpdated Oct 19, 2023

Home-based Training and Supplementation in DM1 Patients

A Phase 3 interventional study of Mult-ingredient supplement and Placebo in Myotonic Dystrophy 1, sponsored by McMaster University. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by McMaster University · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Myotonic Dystrophy with a site in Canada — 13 open to participants now, 16 under way, 4 of them phase 3. Myotonic Dystrophy · Canada.

Planned enrollment
6th of 25
60 · median 32
Started
2024
with 7 others
Phase 3
4 of 28
3 open now
Primary completion
2025-01
later than 0 of 15 live
Registered
13th of 28
by date
Lead sponsor
2 of 28
McMaster University

Among the 28 studies in Myotonic Dystrophy with a site in Canada, this one is the 6th largest by planned enrollment of the 25 interventional ones that give a count, is one of 8 that started in 2024, is one of 4 in phase 3, reaches primary completion later than 0 of the 15 other live ones, and was the 13th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

13 of the 28 studies in Myotonic Dystrophy with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 19 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Myotonic Dystrophy with a site in Canada, or all of them as a file.
02

Study summary

Myotonic dystrophy type 1 (DM1) is a rare genetic disease that affects about 1 in 2100 people. Patients diagnosed with DM1 present with many symptoms, however, their muscles are mainly affected. DM1 patients experience a gradual loss of muscle, followed by an increase in body fat percentage, which makes them weaker, resulting in difficulties to perform activities of daily living, such as climbing stairs, and understandably, this affects their quality of life. DM1 currently does not have a cure. Therefore, it is very important to find ways in which we can help DM1 patients to improve their symptoms, and hopefully, improve their quality of life, and possibly improve disease prognosis. Exercise is known to improve muscle quality and function. In addition, we hypothesize that a multi-ingredient supplement (MIS) for muscle health and antioxidants for fat loss, might show improved benefits on top of exercise. Therefore, we will investigate the effects of 16-week home-based concurrent training, with MIS or placebo, on body composition, and functional measures. Lastly, we will investigate muscle adaptations in DM1 and following study intervention

Read the detailed description

The present study will target patients (male and female) that have been clinically diagnosed with myotonic dystrophy type 1 with 100-1000 CTG repeats, between the ages of 19 - 60. In addition, a healthy population will serve as baseline controls, and they will be matched for age and sex, to the DM1 patients.

A total of 40 DM1 patients and 20 healthy controls will be recruited. DM1 patients will be randomized to 20 in the active group and 20 in the placebo. Both males and females will be recruited, targeting 20 males and 20 females. Corresponding 10 healthy males and 10 healthy females will be matched for sex and age, and only participate in baseline visits, measures, and sample collection.

Home-based concurrent training (HBCT) represents an exercise intervention with minimal barriers to entry. Our study will assess the effectiveness of this intervention, in combination with a multi-ingredient supplement (MIS) containing protein, creatine, antioxidants, and other dietary supplements in patients with DM1, in improving functional, clinical, and strength measures, as well as the quality of life, as assessed by scores in questionnaires. In addition, we will investigate adaptations to skeletal muscle following HBCT and MIS.

A randomized clinical trial of DM1 patients. Our study will include exercise as the over-arching intervention, with two groups nested within, DM1 patients randomized to MIS and placebo, both of which will undergo 16 weeks of home-based exercise training. Measurements and samples will be collected before and after the study intervention. A third group will include age and sex-matched healthy controls. This group will not undergo training + supplement intervention and will be used for baseline comparisons between healthy participants and DM1 patients.

Study procedures will include blood draws and muscle biopsies in each visit. In addition, participants will be asked to undergo a cardiorespiratory fitness test (VO2MAX test), a battery of functional tests (6-minute walk test, 5x sit-to-stand, one leg standing, 4-stair climb), strength testing (grip strength and knee extension tests) and lastly, clinical procedures, including ECGs and spirometry. Measurements and sample collection will be done before and after the study intervention.

03

Conditions studied

  • Myotonic Dystrophy 1

Browse trials for

Keywords

  • myotonic dystrophy, skeletal muscle, mitochondria
04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Age and sex-matched controls inclusion criteria:

  • Healthy men and women
  • Normal (BMI 18.5 - 24.9 kg/m2)

Inclusion criteria

Inclusion Criteria for DM1 patients:

  • Male or female clinically diagnosed with DM1 (age 19 - 60 y).
  • CTG repeats 100-1000.
  • Normal weight (BMI 18.5 - 24.9 kg/m2) or overweight (BMI 25 - 29.9 kg/m2).
  • Physically inactive (\< 1 hour of formal exercise/week).
  • 6-minute walk test score between 250 - 500 meters
  • with PR interval \< 225 ms and QRS duration \< 125 ms.

Exclusion criteria

Exclusion Criteria for DM1 patients:

  • Smoking
  • Obese ( > 30.0 kg/m2)
  • Physically active (> 1-2 hour of formal exercise/week)
  • 6-minute walk test score \<250 meters, chronic (> 2 weeks)
  • Use of narcotic analgesic or anti-inflammatory drugs
  • Type 1 or 2 diabetes (more than one anti-diabetic drug)
  • Cardiovascular disease (recent myocardial infarction (\< 6 months)
  • Uncontrolled hypertension requiring more than 2 medications.
  • Congestive heart failure requiring more than one medication for control.
  • Cardiac conduction block (as above)
  • Renal disease (creatinine > 140)
  • Known liver disease
  • Cognitive impairments limiting ability to provide
  • Previous stroke with residual hemiparesis
  • Active musculoskeletal injuries and/or severe osteoarthritis
  • Significant weight loss in the 3-month period prior to the study
  • Severe peripheral neuropathy
  • Severe osteoporosis
  • Use of medications known to affect protein metabolism (i.e. )
  • Chronic obstructive or restrictive pulmonary disease (FVC \< 70% of age predicted mean value)
  • Asthma requiring more than two medications.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    DM1 + HBEXT + MIS

    Participants will be asked to undergo 16 weeks of home-based training and asked to take one dose of a multi-ingredient supplement per day.

    Dietary Supplement: Mult-ingredient supplement · Behavioral: Concurrent exercise training

  • Placebo comparator
    DM1 + HBEXT + PLA

    Participants will be asked to undergo 16 weeks of home-based training and asked to take one dose of a multi-ingredient supplement placebo per day.

    Dietary Supplement: Placebo · Behavioral: Concurrent exercise training

  • No intervention
    CONTROL

    Healthy control subjects who will not undergo study intervention and will be used for baseline measurements and outcomes.

Interventions

  • Dietary supplementMult-ingredient supplement

    A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin

  • Dietary supplementPlacebo

    The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.

  • BehavioralConcurrent exercise training

    All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.

06

What researchers measure

Primary outcomes

  1. Body Composition Index

    Changes in ratio of fat-free mass to fat mass index as assessed via DEXA scan

    Time frame: 4 months from enrolment

  2. VO2 Max

    Changes in cardiorespiratory fitness proxy measure as assessed via VO2 max testing

    Time frame: 4 months from enrolment

Secondary outcomes

  1. 6-minute walk test

    Changes in number of meters walked during the 6 minute walk test

    Time frame: 4 months from enrolment

  2. 5x sit to stand

    Changes in time (s) that is needed to complete 5x sit to stand from a chair

    Time frame: 4 months from enrolment

  3. Timed up and go

    Changes in the time (seconds) needed to complete a timed up and go test

    Time frame: 4 months from enrolment

  4. Leg muscle strength

    Changes in maximal isometric knee extension via Biodex in N\*m

    Time frame: 4 months from enrolment

  5. Grip strength

    Changes in grip strength (kg) using a hand dynamometer

    Time frame: 4 months from enrolment

  6. Single leg stance test

    Changes in whether patients can stand on one leg for 10 s or not

    Time frame: 4 months from enrolment

  7. Muscle fibre cross sectional area

    Changes in fibre cross sectional area from a muscle biopsy of vastus lateralis using immunoflourescence

    Time frame: 4 months from enrolment

  8. Muscle stem cell mitochondrial function

    Changes in mitochondrial function in isolated muscle stem cells of DM1 patients via seahorse assay

    Time frame: 4 months from enrolment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Jan 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 8, 2023
StartEst.
Jan 1, 2024
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2025
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05848830
Responsible party
Mark Tarnopolsky (Principal Investigator, Professor, Director of Neuromuscular and Neurometabolic Clinic, McMaster University) — Principal investigator
First posted
May 8, 2023
Start date
Jan 1, 2024 (estimated)
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Oct 19, 2023

Study contacts

Mark A Tarnopolsky, MD, PhD
Contact
tarnopol@mcmaster.ca
905-525-9140 ext. 75226
Joshua P Nederveen, PhD
Contact
nedervj@mcmaster.ca
905-902-0583

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion